Portal-Núñez S, Ardura J A, Lozano D, Martínez de Toda I, De la Fuente M, Herrero-Beaumont G, Largo R, Esbrit P
Bone and Joint Research Unit, The Institution of Health Research (IIS)-Fundación Jiménez Díaz, UAM, Madrid, Spain
The Institution of Applied Molecular Medicine (IMMA), Universidad San Pablo CEU Madrid, Spain.
Bone Joint Res. 2018 Jan;7(1):58-68. doi: 10.1302/2046-3758.71.BJR-2016-0242.R2.
Oxidative stress plays a major role in the onset and progression of involutional osteoporosis. However, classical antioxidants fail to restore osteoblast function. Interestingly, the bone anabolism of parathyroid hormone (PTH) has been shown to be associated with its ability to counteract oxidative stress in osteoblasts. The PTH counterpart in bone, which is the PTH-related protein (PTHrP), displays osteogenic actions through both its N-terminal PTH-like region and the C-terminal domain.
We examined and compared the antioxidant capacity of PTHrP (1-37) with the C-terminal PTHrP domain comprising the 107-111 epitope (osteostatin) in both murine osteoblastic MC3T3-E1 cells and primary human osteoblastic cells.
We showed that both N- and C-terminal PTHrP peptides at 100 nM decreased reactive oxygen species production and forkhead box protein O activation following hydrogen peroxide (HO)-induced oxidation, which was related to decreased lipid oxidative damage and caspase-3 activation in these cells. This was associated with their ability to restore the deleterious effects of HO on cell growth and alkaline phosphatase activity, as well as on the expression of various osteoblast differentiation genes. The addition of Rp-cyclic 3',5'-hydrogen phosphorothioate adenosine triethylammonium salt (a cyclic 3',5'-adenosine monophosphate antagonist) and calphostin C (a protein kinase C inhibitor), or a PTH type 1 receptor antagonist, abrogated the effects of N-terminal PTHrP, whereas protein phosphatase 1 (an Src kinase activity inhibitor), SU1498 (a vascular endothelial growth factor receptor 2 inhibitor), or an anti osteostatin antiserum, inhibited the effects of C-terminal PTHrP.
These findings indicate that the antioxidant properties of PTHrP act through its N- and C-terminal domains and provide novel insights into the osteogenic action of PTHrP.: S. Portal-Núñez, J. A. Ardura, D. Lozano, I. Martínez de Toda, M. De la Fuente, G. Herrero-Beaumont, R. Largo, P. Esbrit. Parathyroid hormone-related protein exhibits antioxidant features in osteoblastic cells through its N-terminal and osteostatin domains. 2018;7:58-68. DOI: 10.1302/2046-3758.71.BJR-2016-0242.R2.
氧化应激在绝经后骨质疏松症的发生和发展中起主要作用。然而,经典抗氧化剂无法恢复成骨细胞功能。有趣的是,甲状旁腺激素(PTH)的骨合成代谢已被证明与其抵抗成骨细胞氧化应激的能力有关。骨中的PTH对应物,即甲状旁腺激素相关蛋白(PTHrP),通过其N端PTH样区域和C端结构域发挥成骨作用。
我们在小鼠成骨MC3T3-E1细胞和原代人成骨细胞中检测并比较了PTHrP(1-37)与包含107-111表位(骨抑素)的C端PTHrP结构域的抗氧化能力。
我们发现,100 nM的N端和C端PTHrP肽均可降低过氧化氢(H₂O₂)诱导氧化后的活性氧生成和叉头框蛋白O激活,这与这些细胞中脂质氧化损伤和半胱天冬酶-3激活的减少有关。这与它们恢复H₂O₂对细胞生长、碱性磷酸酶活性以及各种成骨细胞分化基因表达的有害影响的能力有关。添加Rp-环3',5'-氢硫代磷酸腺苷三乙铵盐(一种环3',5'-单磷酸腺苷拮抗剂)和钙泊三醇C(一种蛋白激酶C抑制剂)或PTH 1型受体拮抗剂可消除N端PTHrP的作用,而蛋白磷酸酶1(一种Src激酶活性抑制剂)、SU1498(一种血管内皮生长因子受体2抑制剂)或抗骨抑素抗血清则可抑制C端PTHrP的作用。
这些发现表明,PTHrP的抗氧化特性通过其N端和C端结构域发挥作用,并为PTHrP的成骨作用提供了新的见解。:S. Portal-Núñez,J. A. Ardura,D. Lozano,I. Martínez de Toda,M. De la Fuente,G. Herrero-Beaumont,R. Largo,P. Esbrit。甲状旁腺激素相关蛋白通过其N端和骨抑素结构域在成骨细胞中表现出抗氧化特性。2018;7:58-68。DOI:10.1302/2046-